Soluble intercellular adhesion molecule-1 in sera from patients with chronic hepatitis C undergoing interferon treatment.
To study the influence of interferon therapy on soluble intercellular adhesion molecule-1 we measured sICAM-1 levels in 22 patients with type C chronic hepatitis treated with interferon. We also studied 9 healthy subjects as control group. The results showed statistically significant higher levels of sICAM-1 in patients with liver disease than in the controls. The sICAM-1 baseline levels were similar in patients with chronic active hepatitis or cirrhosis but, during therapy, these levels decreased only in patients with chronic hepatitis. After IFN withdrawal sICAM-1 levels rebounded to initial values.
Sonnante
A M
AM
Laboratorio di Patologia Clinica, Ospedale S. de Bellis, IRCCS Castellana-Grotte (BA), Italy.
Cozzolongo
R
R
Cuppone
R
R
De Michele
G
G
Manghisi
O G
OG
Quaranta
M
M
D000998:Antiviral Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D019698:Hepatitis C, Chronic / Q000097:blood / Q000276:immunology / Q000628:therapy*; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood*; D007370:Interferon Type I / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012995:Solubility
D000998:Antiviral Agents; D007370:Interferon Type I; D016898:Interferon-alpha; D011994:Recombinant Proteins; D018799:Intercellular Adhesion Molecule-1